{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:53:40Z","timestamp":1761562420791},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T00:00:00Z","timestamp":1537401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s10620-018-5288-9","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T11:36:24Z","timestamp":1537443384000},"page":"4-6","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Optimal PPI Dosing for Improving GERD Symptoms: Is Timing Everything?"],"prefix":"10.1007","volume":"64","author":[{"given":"David Y.","family":"Graham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,20]]},"reference":[{"key":"5288_CR1","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1136\/gut.30.11.1523","volume":"30","author":"B Joelsson","year":"1989","unstructured":"Joelsson B, Johnsson F. Heartburn\u2014the acid test. Gut. 1989;30:1523\u20131525.","journal-title":"Gut"},{"key":"5288_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/0016-5085(89)90890-1","volume":"96","author":"JL Smith","year":"1989","unstructured":"Smith JL, Opekun AR, Larkai E, Graham DY. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease. Gastroenterology. 1989;96:683\u2013689.","journal-title":"Gastroenterology"},{"key":"5288_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2036.1992.tb00550.x","volume":"6","author":"SG Chiverton","year":"1992","unstructured":"Chiverton SG, Howden CW, Burget DW, Hunt RH. Omeprazole (20\u00a0mg) daily given in the morning or evening: a comparison of effects on gastric acidity, and plasma gastrin and omeprazole concentration. Aliment Pharmacol Ther. 1992;6:103\u2013111.","journal-title":"Aliment Pharmacol Ther"},{"key":"5288_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2036.1992.tb00057.x","volume":"6","author":"SW Sanders","year":"1992","unstructured":"Sanders SW, Tolman KG, Greski PA, et al. The effects of lansoprazole, a new H\u2009+\u2009, K(+)-ATPase inhibitor, on gastric pH and serum gastrin. Aliment Pharmacol Ther. 1992;6:359\u2013372.","journal-title":"Aliment Pharmacol Ther"},{"key":"5288_CR5","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.cgh.2017.09.033","volume":"6","author":"DY Graham","year":"2018","unstructured":"Graham DY, Tansel A. Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol. 2018;6:800\u2013808.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5288_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1146\/annurev.pa.35.040195.001425","volume":"35","author":"G Sachs","year":"1995","unstructured":"Sachs G, Shin JM, Briving C, Wallmark B, Hersey S. The pharmacology of the gastric acid pump: the H\u2009+\u2009, K\u2009+\u2009ATPase. Annu Rev Pharmacol Toxicol. 1995;35:277\u2013305.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5288_CR7","doi-asserted-by":"publisher","unstructured":"Waghray A, Wagray N, Perzynski AT, et al. Optimal omeprazole dosing and symptom control\u2014a randomized controlled trial (OSCAR TRIAL). Dig Dis Sci. (Epub ahead of print). \n                    https:\/\/doi.org\/10.1007\/s10620-018-5235-9\n                    \n                  .","DOI":"10.1007\/s10620-018-5235-9"},{"key":"5288_CR8","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1023\/A:1018891106425","volume":"42","author":"RJ Brummer","year":"1997","unstructured":"Brummer RJ, Geerling BJ, Stockbrugger RW. Initial and chronic gastric acid inhibition by lansoprazole and omeprazole in relation to meal administration. Dig Dis Sci. 1997;42:2132\u20132137.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"5288_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1159\/000489557","volume":"36","author":"D Boltin","year":"2018","unstructured":"Boltin D, Zvidi I, Raskin M, Kayless H, et al. Effect of postprandial administration of esomeprazole on reflux symptoms in gastroesophageal reflux disease: a randomized, controlled trial. Dig Dis. 2018;36:257\u2013263.","journal-title":"Dig Dis"},{"key":"5288_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2036.2009.04032.x","volume":"30","author":"SJ Spechler","year":"2009","unstructured":"Spechler SJ, Barker PN, Silberg DG. Clinical trial: intragastric acid control in patients who have Barrett\u2019s oesophagus\u2014comparison of once- and twice-daily regimens of esomeprazole and lansoprazole. Aliment Pharmacol Ther. 2009;30:138\u2013145.","journal-title":"Aliment Pharmacol Ther"},{"key":"5288_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1046\/j.1365-2036.2003.01405.x","volume":"17","author":"M Frazzoni","year":"2003","unstructured":"Frazzoni M, De A, Grisendi A, Savarino V. Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. Aliment Pharmacol Ther. 2003;17:235\u2013241.","journal-title":"Aliment Pharmacol Ther"},{"key":"5288_CR12","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S1542-3565(05)00860-8","volume":"4","author":"R Fass","year":"2006","unstructured":"Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol. 2006;4:50\u201356.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-018-5288-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-018-5288-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:03:56Z","timestamp":1568919836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-018-5288-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,20]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["5288"],"URL":"https:\/\/doi.org\/10.1007\/s10620-018-5288-9","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,20]]},"assertion":[{"value":"20 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Graham is a consultant for RedHill Biopharma regarding novel <i>H. pylori<\/i> therapies. He has also received research support for culture of <i>Helicobacter pylori<\/i> and is the PI of an international study of the use of antimycobacterial therapy for Crohn\u2019s disease. He is also a consultant for BioGaia in relation to probiotic therapy for <i>H. pylori<\/i> infection and for Takeda in relation to <i>H. pylori<\/i> therapies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}